Vaginal microbes play a crucial role in maintaining genital health by offering powerful defenses against infections. Unlike healthy microbiota in other parts of the body, such as the gastrointestinal tract, the vaginal microbiota is distinctive for its low diversity with lactobacilli comprising nearly 95% of the total bacteria. Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus iners, are the most represented in the vagina of healthy women
However, L. iners is distinct from the others because of its variable connections with genital health. This blog will describe the unique characteristics of L. iners as they pertain to vaginal health as well as the controversies surrounding their actions. Ideas on how this knowledge may influence modulation therapy will be discussed.
L. iners in the vaginal microbiome, in brief
As a fundamental contributor to genital and reproductive health, the vaginal microbiome defends against bacterial vaginosis and sexually transmitted infections. Lactobacilli species, including L. crispatus, L. gasseri, L. jensenii, and L. iners protect against many pathogens in diverse ways. These include competing against pathogens for nutrients, producing lactic acid which acidifies the environment and kills pathogens, producing bacteriocins that also suppress harmful bacteria, creating a physical barrier against pathogen adhesion, and exerting immune modulatory effects.
Various factors like menstruation, pregnancy, sexual practices, vaginal douching, and antibiotics can swiftly disturb the vaginal ecosystem, potentially causing or facilitating conditions including bacterial vaginosis (BV), sexually transmitted infections (STIs), and pregnancy-related complications.
First identified in 1999, L. iners is the most common and persistent vaginal species in reproductive-aged women across the world. Under fluctuating conditions such as high pH or dysbiosis — when other species may die — L. iners survives with remarkable consistency and adaptability. Unlike the other primary vaginal lactobacilli species like L. crispatus, L. jensenii, and L. gasseri, it is implicated in both healthy and disease states.
L. iners and disease
In bacterial vaginosis (BV), pathogens interrupt the healthy vaginal habitat, potentially elevating the risk for sexually transmitted diseases and leading to adverse outcomes regarding reproductive health.
Researchers have found that levels of protection vary by type of dominant species. Whereas the presence of L. crispatus is linked with good health in numerous studies, dominance by L. iners is not always reported to offer protection against vaginal dysbiosis. Vaginal microbiota primarily dominated by L. iners have been linked to a higher likelihood of experiencing bacterial vaginosis.
A 2023 systematic review and meta-analyses looked at the associations between L. iners compared with L. crispatus in outcomes in BV and Chlamydia trachomatis (CT) – as well as in other sexually-transmitted infections.
Bacterial vaginosis
In the three BV studies included in the meta-analysis, L.iners–dominated microbiota had two times the prevalence of BV compared with microbiota dominated by L. crispatus.
Chlamydia trachomatis
In the six CT studies included in the meta-analysis, L.iners–dominated microbiota were observed to have a 3.4-fold higher probability of CT compared with microbiota dominated by L. crispatus.
The researchers were unable to make conclusions regarding links between L. iners and the other outcomes (human papillomavirus, cervical dysplasia, human immunodeficiency virus, genital herpes, Trichomonas vaginalis, and Neisseria gonorrhoeae) because “evidence was too sparse to perform meta-analysis.” The authors cautioned that a high risk of bias and low-quality evidence in these studies makes interpretation regarding the impact of L. iners on sexual health outcomes difficult.
The link between L. iners and an elevated risk of negative outcomes is not consistent, leading to widespread debate regarding its role in the vaginal microbiome.
Possible mechanisms
Recent research points to several unique characteristics of L. iners, which may at least partially account for some of its inconsistent role in vaginal health and disease.
Lactic acid production
Lactic acid exists as two isomers and both acidify (lower the pH) the vaginal milieu, a key protection against pathogens. L-lactic acid is derived from both the vaginal epithelia and Lactobacillus spp., while D-lactic acid is produced by specific lactobacilli. While there are observed differences in lactic acid production by diverse lactobacilli, including L. iners, the significance is not clear.
Strain
Of the vaginal Lactobacillus spp., L. iners has the smallest genetic blueprint but its different strains show more genetic diversity. The specific combination of L. iners strains in the vaginal microbiome has a broad range of functions that help the species thrive in different vaginal environments. However, current studies often group together strain-specific effects, leading to less accurate assessments of the risks associated with this bacterial species.
Gene expression
L. liners gene activity in the vaginal microbiome shows its adaptability to environmental changes. The ability of L. iners to produce a protein toxin named inerolysin influences its ability to acquire nutrients from the vaginal environment and may give L. iners a competitive advantage when nutrients are scarce, especially under potentially adverse conditions, such as BV, when other lactobacilli species struggle to colonize the vagina. Furthermore, new research suggests that additional bacteriocin production as well as selective sensitivity to bacteriocins may factor into the adaptation of L.iners in hostile vaginal conditions.
Going forward
Though somewhat admirable, the persistence and plasticity of L. iners in the vaginal environment make for a challenging quandary when it comes to disease protection. Other lactobacilli-containing therapies have shown some encouraging results in conditions such as BV, CT, and other disorders such as human immunodeficiency virus ( HIV), human papillomavirus (HPV) as well as in obstetric and reproductive disorders.
Certain strains or genes of L. iners could potentially serve as targets for therapeutic adjustments to the vaginal microbiota. An innovative approach might involve stabilizing the L. iners microbiota, particularly those linked to a higher risk of BV, by transitioning them to a more resilient state characterized by L. iners strains resistant to fluctuations.
Takeaway
Vaginal microbes, particularly lactobacilli, play a vital role in safeguarding genital health by defending against infections. While L. crispatus, L. gasseri, and L. jensenii are associated with positive outcomes, L. iners, one of the most common vaginal species, shows unique adaptability under fluctuating conditions but has controversial connections with health. Studies indicate L.iners–dominated microbiota may elevate the risk of bacterial vaginosis and Chlamydia trachomatis and possibly other outcomes. The many questions regarding L. iners make for challenging issues in understanding its role in the vaginal microbiome. Innovative therapeutic approaches targeting specific L. iners strains or genes could potentially modulate the vaginal microbiota and address associated health risks.
Image by Gerd Altmann from Pixabay
Key references
Aldunate, Muriel et al. “Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis.” Frontiers in physiology vol. 6 164. 2 Jun. 2015, doi:10.3389/fphys.2015.00164
Alonzo Martínez, Melanie C et al. “Study of the Vaginal Microbiota in Healthy Women of Reproductive Age.” Microorganisms vol. 9,5 1069. 15 May. 2021, doi:10.3390/microorganisms9051069
Carter, Kayla A et al. “Epidemiologic Evidence on the Role of Lactobacillus iners in Sexually Transmitted Infections and Bacterial Vaginosis: A Series of Systematic Reviews and Meta-Analyses.” Sexually transmitted diseases vol. 50,4 (2023): 224-235. doi:10.1097/OLQ.0000000000001744
Chee, Wallace Jeng Yang et al. “Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health.” Microbial cell factories vol. 19,1 203. 7 Nov. 2020, doi:10.1186/s12934-020-01464-4
Falsen, E et al. “Phenotypic and phylogenetic characterization of a novel Lactobacillus species from human sources: description of Lactobacillus iners sp. nov.” International journal of systematic bacteriology vol. 49 Pt 1 (1999): 217-21. doi:10.1099/00207713-49-1-217
Holm, Johanna B et al. “Lactobacillus iners and genital health: molecular clues to an enigmatic vaginal species.” Current infectious disease reports vol. 25,4 (2023): 67-75. doi:10.1007/s11908-023-00798-5
Kroon, Samuel J et al. “Cervicovaginal microbiota, women’s health, and reproductive outcomes.” Fertility and sterility vol. 110,3 (2018): 327-336. doi:10.1016/j.fertnstert.2018.06.036
Li, Lili et al. “The First Lanthipeptide from Lactobacillus iners, Inecin L, Exerts High Antimicrobial Activity against Human Vaginal Pathogens.” Applied and environmental microbiology vol. 89,3 (2023): e0212322. doi:10.1128/aem.02123-22
Li, Wendy, and Zhanshan Sam Ma. “Dominance network analysis of the healthy human vaginal microbiome not dominated by Lactobacillus species.” Computational and structural biotechnology journal vol. 18 3447-3456. 10 Nov. 2020, doi:10.1016/j.csbj.2020.10.033
López-Moreno, Ana, and Margarita Aguilera. “Vaginal Probiotics for Reproductive Health and Related Dysbiosis: Systematic Review and Meta-Analysis.” Journal of clinical medicine vol. 10,7 1461. 2 Apr. 2021, doi:10.3390/jcm10071461
Macklaim, Jean M et al. “At the crossroads of vaginal health and disease, the genome sequence of Lactobacillus iners AB-1.” Proceedings of the National Academy of Sciences of the United States of America vol. 108 Suppl 1,Suppl 1 (2011): 4688-95. doi:10.1073/pnas.1000086107
McKinnon, Lyle R et al. “The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission.” AIDS research and human retroviruses vol. 35,3 (2019): 219-228. doi:10.1089/AID.2018.0304
Moreno, Inmaculada, and Carlos Simon. “Deciphering the effect of reproductive tract microbiota on human reproduction.” Reproductive medicine and biology vol. 18,1 40-50. 1 Nov. 2018, doi:10.1002/rmb2.12249
Nilsen, Trine et al. “Novel Selective Inhibition of Lactobacillus iners by Lactobacillus-Derived Bacteriocins.” Applied and environmental microbiology vol. 86,20 e01594-20. 1 Oct. 2020, doi:10.1128/AEM.01594-20
O’Hanlon, Deirdre Elizabeth et al. “Vaginal pH measured in vivo: lactobacilli determine pH and lactic acid concentration.” BMC microbiology vol. 19,1 13. 14 Jan. 2019, doi:10.1186/s12866-019-1388-8
Oyadiran, Oluwafemi Temitayo et al. “Effect of intake of probiotics and probiotic fermented foods on clinical outcomes among people living with HIV: A systematic review and meta-analysis.” Tropical medicine & international health : TM & IH, 10.1111/tmi.13955. 19 Dec. 2023, doi:10.1111/tmi.13955
Parolin, Carola et al. “Lactobacillus crispatus BC5 Interferes With Chlamydia trachomatis Infectivity Through Integrin Modulation in Cervical Cells.” Frontiers in microbiology vol. 9 2630. 6 Nov. 2018, doi:10.3389/fmicb.2018.02630
Petrova, Mariya I et al. “Lactobacillus iners: Friend or Foe?.” Trends in microbiology vol. 25,3 (2017): 182-191. doi:10.1016/j.tim.2016.11.007
Petrova, Mariya I et al. “Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health.” Frontiers in physiology vol. 6 81. 25 Mar. 2015, doi:10.3389/fphys.2015.00081
Rampersaud, Ryan et al. “Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners.” Journal of bacteriology vol. 193,5 (2011): 1034-41. doi:10.1128/JB.00694-10
Ravel, Jacques et al. “Vaginal microbiome of reproductive-age women.” Proceedings of the National Academy of Sciences of the United States of America vol. 108 Suppl 1,Suppl 1 (2011): 4680-7. doi:10.1073/pnas.1002611107
Rousseau, V et al. “Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms.” Anaerobe vol. 11,3 (2005): 145-53. doi:10.1016/j.anaerobe.2004.12.002
Tachedjian, Gilda et al. “The implausible “in vivo” role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota.” Microbiome vol. 6,1 29. 6 Feb. 2018, doi:10.1186/s40168-018-0418-3
Tomaiuolo, Rossella et al. “Microbiota and Human Reproduction: The Case of Female Infertility.” High-throughput vol. 9,2 12. 3 May. 2020, doi:10.3390/ht9020012
van de Wijgert, Jhhm, and M C Verwijs. “Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs.” BJOG : an international journal of obstetrics and gynaecology vol. 127,2 (2020): 287-299. doi:10.1111/1471-0528.15870
Vaneechoutte, Mario. “Lactobacillus iners, the unusual suspect.” Research in microbiology vol. 168,9-10 (2017): 826-836. doi:10.1016/j.resmic.2017.09.003
Verstraelen, Hans et al. “Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora.” BMC microbiology vol. 9 116. 2 Jun. 2009, doi:10.1186/1471-2180-9-116
Witkin, Steven S et al. “Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections.” mBio vol. 4,4 e00460-13. 6 Aug. 2013, doi:10.1128/mBio.00460-13
Xholli, Anjeza et al. “Gut Microbiota and Endometriosis: Exploring the Relationship and Therapeutic Implications.” Pharmaceuticals (Basel, Switzerland) vol. 16,12 1696. 7 Dec. 2023, doi:10.3390/ph16121696
Zheng, Nengneng et al. “Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review.” Frontiers in cellular and infection microbiology vol. 11 792787. 22 Nov. 2021, doi:10.3389/fcimb.2021.792787